tbuckley/cabot-search huggingface dataset:
Evolving Strategies in First-Line Chronic Lymphocytic Leukemia: Is There a Role for Chemoimmunotherapy?
Authors: Jennifer R. Brown, William G. Wierda
Journal: Journal of the National Comprehensive Cancer Network (2019)

With the enormous progress made in treatment and management, many oncologists have called this the golden age of chronic lymphocytic leukemia (CLL). The past few years alone have seen the approval of multiple agents, including small molecule inhibitors that have led to longer, more durable periods of disease control. However, the introduction of these new drugs into the armamentarium has raised an important question regarding standard of care: is there still a role for chemoimmunotherapy in the first-line setting? At the NCCN 2019 Annual Congress: Hematologic Malignancies, Drs. William G. Wierda and Jennifer R. Brown presented opposing sides of the debate.
Integration of electronic patient-reported outcomes into clinical workflows within the Epic electronic medical record.
Authors: Heather A Rosett, Kris Herring, William Ratliff, Bridget F. Koontz, Yousuf Zafar, Thomas William LeBlanc
Journal: Journal of Clinical Oncology (2019)

102 Background: Electronic patient-reported outcome measures (ePROs) offer a new strategy for symptom assessment that can improve quality of life and prolong survival in routine cancer care. However, ePRO systems are often separate from existing electronic medical records (EMRs) and not well integrated into oncology clinics. In this pilot project, we assessed the feasibility and utility of integrating ePROs into our existing EMR and clinical workflows. Methods: The 10-question Edmonton Symptom Assessment Scale (ESAS) was integrated into the Epic EMR at three outpatient clinics in the Duke Cancer Institute. Patients with active MyChart accounts were offered the ESAS survey prior to their visit, via the patient portal. ePRO data were routed to clinicians in tabular and graphical formats. A “SmartPhrase” facilitated easy data integration into clinical notes. We subsequently interviewed clinicians and optimized workflows. Several patient engagement strategies were used, including automated messages, phone call reminders, and electronic tablets, to increase response rate. Results: It was feasible to quickly customize and activate an ePRO in Epic. Over 10 months, 161 patients completed 208 ePRO surveys. Initially, 10-20% of eligible patients completed the MyChart questionnaire. Patient engagement strategies, including phone calls and personalized MyChart messages, had little effect. Ultimately, tablets were introduced in the clinic check-in process, increasing response rates to &gt;90%. Clinicians reported positive regard for the system, and an impact on patient symptom management. Clinician workflow optimization resulted in minimal “clicks” in the EMR, and the SmartPhrase was used in 128 clinical notes. Conclusions: Integration of ePROs into the clinical setting poses three challenges: technical implementation, workflow optimization, and patient engagement. While technical implementation is important, it was the easiest to solve, with patient engagement as the greatest barrier. Clinicians value an integrated ePRO system that automatically routes data to the clinical note. The key to successful ePRO integration is in ease of use for both patients and clinicians.
Correction to: miR-195-5p/NOTCH2-mediated EMT modulates IL-4 secretion in colorectal cancer to affect M2-like TAM polarization
Authors: Xiaobin Lin, Shuyi Wang, Min Sun, Chunxiao Zhang, Chen Wei, Chaogang Yang, Rongzhang Dou, Qing Liu, Bin Xiong
Journal: Journal of Hematology & Oncology (2019)

In the original article [1], the terms 'osISET' and 'ISET' within the 'CTC capture' sub-section of the Materials and Methods section have both been replaced with 'CTCBIOPSY®'.
Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder
Authors: Arthur Robin Williams, Hillary Samples, Stephen Crystal, Mark Olfson
Journal: American Journal of Psychiatry (2019)

Although buprenorphine treatment reduces risk of overdose and death in opioid use disorder, most patients discontinue treatment within a few weeks or months. Adverse health outcomes following buprenorphine discontinuation were compared among patients who were successfully retained beyond 6 months of continuous treatment, a minimum treatment duration recently endorsed by the National Quality Forum.A retrospective longitudinal cohort analysis was performed using the MarketScan multistate Medicaid claims database (2013-2017), covering 12 million beneficiaries annually. The sample included adults (18-64 years of age) who received buprenorphine continuously for ≥180 days by cohorts retained for 6-9 months, 9-12 months, 12-15 months, and 15-18 months. For outcome assessment in the postdiscontinuation period, patients had to be continuously enrolled in Medicaid for 6 months after buprenorphine discontinuation. Primary adverse outcomes included all-cause emergency department visits, all-cause inpatient hospitalizations, opioid prescriptions, and drug overdose (opioid or non-opioid).Adverse events were common across all cohorts, and almost half of patients (42.1%-49.9%) were seen in the emergency department at least once. Compared with patients retained on buprenorphine for 6-9 months (N=4,126), those retained for 15-18 months (N=931) had significantly lower odds of emergency department visits (odds ratio=0.75, 95% CI=0.65-0.86), inpatient hospitalizations (odds ratio=0.79, 95% CI=0.64-0.99), and filling opioid prescriptions (odds ratio=0.67, 95% CI=0.56-0.80) in the 6 months following discontinuation. Approximately 5% of patients across all cohorts experienced one or more medically treated overdoses.Risk of acute care service use and overdose were high following buprenorphine discontinuation irrespective of treatment duration. Superior outcomes became significant with treatment duration beyond 15 months, although rates of the primary adverse outcomes remained high.
Response of nivolumab monotherapy in 124 Japanese patients with advanced melanoma: Interim analysis of prospective observational study (CREATIVE study)
Authors: N. Yamazaki, A. Takahashi, K. Namikawa, T. Takenouchi, Y. Nakamura, S. Kitano, T. Fujita, K. Kubota, T. Yamanaka, Y. Kawakami
Journal: Annals of Oncology (2019)
Altered Risk for Cardiovascular Events With Changes in the Metabolic Syndrome Status
Authors: Sehoon Park, Soojin Lee, Yaerim Kim, Yeonhee Lee, Min Woo Kang, Kyungdo Han, Seung Seok Han, Hajeong Lee, Jung Pyo Lee, Kwon Wook Joo, Chun Soo Lim, Yon Su Kim, Dong Ki Kim
Journal: Annals of Internal Medicine (2019)

Population-scale evidence for the association between dynamic changes in metabolic syndrome (MetS) status and alterations in the risk for major adverse cardiovascular events (MACE) is lacking.To investigate whether recovery from or development of MetS in a population is associated with an altered risk for MACE.Nationwide cohort study.An analysis based on the National Health Insurance Database of Korea.A total of 27 161 051 persons who received national health screenings from 2009 to 2014 were screened. Those with a history of MACE were excluded. We determined the MetS status of 9 553 042 persons using the following harmonizing criteria: MetS-chronic (n = 1 486 485), MetS-developed (n = 587 088), MetS-recovery (n = 538 806), and MetS-free (n = 6 940 663).The outcome was the occurrence of MACE, including acute myocardial infarction, revascularization, and acute ischemic stroke, identified from the claims database. The incidence rate ratios (IRRs) were calculated with adjustments for body mass index, comorbidity scores, previous metabolic variables, and other clinical or demographic variables.At a median follow-up of 3.54 years, the MetS-recovery group (incidence rate, 4.55 per 1000 person-years) had a significantly lower MACE risk (adjusted IRR, 0.85 [95% CI, 0.83 to 0.87]) than that of the MetS-chronic group (incidence rate, 8.52 per 1000 person-years). The MetS-developed group (incidence rate, 6.05 per 1000 person-years) had a significantly higher MACE risk (adjusted IRR, 1.36 [CI, 1.33 to 1.39]) than that of the MetS-free group (incidence rate, 1.92 per 1000 person-years). Among the MetS components, change in hypertension was associated with the largest difference in MACE risk.Limited assessment of mortality and short follow-up.Recovery from MetS was significantly associated with decreased risk for MACE, whereas development of MetS was associated with increased risk.Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea.
Abstract P375: Coronary Artery Structural Remodeling by Computed Tomography and Cardiovascular Disease; the Coronary Artery Risk Development in Young Adults (CARDIA) Study
Authors: J J Carr, Yaorong Ge, Edmond K Kabagambe, James G Terry, Donald Lloyd-Jones, Aristotelis Papayannis, Daniel A Duprez, Jamal S Rana, Stephen Sidney, David R Jacobs
Journal: Circulation (2017)

Background: Glagov identified cross-sectional enlargement and maintenance of the lumen of the coronary artery (CA) in post-mortem studies as an early feature of atherosclerotic coronary heart disease (CHD) that precedes the development of stenosis, coronary artery calcium (CAC) and plaque rupture. This structural change in the CA wall has been termed positive remodeling. We hypothesized that larger CA cross-sectional areas, consistent with positively remodeled CA, is associated with prevalent or soon-to-be incident coronary heart disease (CHD) and cardiovascular disease (CVD) events. Methods: In 2946 black and white male and female CARDIA participants aged 42-56 years, who had thin-slice (&lt;1 mm), ECG gated, non-contrast coronary CT in 2010-2011, we measured CA cross-sectional area (CSA) in the proximal epicardial CA at 24 pre-specified locations. The mean of all measurements was calculated to provide a summary of all CA (CA CSA_all ). We performed logistic regression with medical-record adjudicated CVD prevalence (n=96) or incidence in the following 3 years (n=27) as the outcome, predicted from this estimate of positive remodeling adjusting for age, race, sex, presence of coronary artery calcium (CAC), and amount of pericardial fat as covariates. Results: CA CSA_all had a mean ± SD 21.2 ± 6.7 mm 2 . The adjusted odds ratio (OR) for having any CVD was 1.06 (95% CI 1.03-1.09, p&lt;0.0001) per mm 2 (Table). ORs for CVD increased across quartiles of CA CSA_all . Corresponding OR for any coronary heart disease (n=66) was not significant, but was significant for stroke (n=42) and for heart failure (n=27). Further adjustment for traditional risk factors assessed in 2010-2011 did not alter these estimates substantially. Conclusion: Individuals with larger CA cross-sectional areas had increased odds of CVD, stroke, and heart failure, but not CHD, independent of CAC and pericardial fat. CA CSA_all may be an imaging biomarker of coronary positive remodeling and provide new insight into progression from subclinical to premature clinical CVD.
Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Authors: Y. Ang, R. Wong, C.S. Tan, M.V. Blanco, Y. Huang, B.C. Goh, R.A. Soo
Journal: Annals of Oncology (2019)
From the threat to the large outbreak: dengue on Reunion Island, 2015 to 2018
Authors: Muriel Vincent, Sophie Larrieu, Pascal Vilain, Aurélie Etienne, Jean-Louis Solet, Claire François, Bénédicte Roquebert, Marie-Christine Jaffar Bandjee, Laurent Filleul, Luce Menudier
Journal: Eurosurveillance (2019)

BackgroundWith more than 300 million infections estimated annually worldwide, dengue is the most prevalent arboviral infection. On Reunion Island, after a large outbreak in 1977-78, only limited episodes of viral circulation or sporadic cases were reported till 2015.AimOur objective was to document and report on the circulation of dengue virus after the occurrence of a small outbreak during austral summer 2015/16 and until the large outbreak of 2018.MethodsBeside the mandatory notification of biologically confirmed dengue cases, additional systems of surveillance were set up: estimation of dengue-like syndrome in people seeking care by their family doctor, surveillance of emergency department visits related to dengue, surveillance of hospitalised dengue patients and deaths classifications.ResultsAfter a moderate outbreak during summer 2015/16 with 231 cases, 2017 was characterised by limited viral circulation (97 cases) which, however, persisted during the austral winter. By February 2018, the number of cases had increased and led to a peak at the beginning of May 2018. More than 6,000 cases were reported this year (dengue virus type 2 only). In addition, six deaths of dengue patients were notified.ConclusionIn 2017, the persistence of transmission during winter created favourable conditions for the emergence of an epidemic during summer 2018. After this moderate epidemic wave, the viral circulation persisted during winter 2018 for the second year, opening the door for the second wave in 2019 and for potential endemisation of the disease on Reunion Island in the near future.
Rates of Laboratory Adverse Events By Chemotherapy Course for Pediatric Acute Leukemia Patients within the Leukemia Electronic Abstraction of Records Network (LEARN)
Authors: Tamara P. Miller, Kelly D Getz, Biniyam Demissei, Karen R. Rabin, Marla Daves, Philip J. Lupo, Michael E. Scheurer, Evanette Burrows, Brian T. Fisher, Robert W. Grundmeier, Judy Lee, Jennifer J. Wilkes, Lena E. Winestone, Maria Monica J. Gramatges, Richard Aplenc
Journal: Blood (2019)
HoxA9 Knockdown Inhibits Proliferation and Induces Cell Death in Human MLL-Rearranged Leukemias.
Authors: Jorg Faber, Andrei V. Krivtsov, Matthew C. Stubbs, Renee Wright, Marry van den Heuvel-Eibrink, Andrew L. Kung, Christian M. Zwaan, Scott A. Armstrong
Journal: Blood (2006)
Chimeric Antigen Receptor 4SCAR-GD2-Modified T Cells Targeting High-Risk and Recurrent Neuroblastoma: A Phase II Multi-Center Trial in China
Authors: Lihua Yang, Xiaoli Ma, Yu-Chen Liu, Wen Zhao, Lihua Yu, Maoquan Qin, Guanghua Zhu, Kai Wang, Xiaodong Shi, Zhaoxia Zhang, Jingfu Wang, Yuan Sun, Lujia Dong, Shih-Ting Tsao, Rui Zhang, Lung-Ji Chang
Journal: Blood (2017)
Overexpression of T-bet in HIV infection is associated with accumulation of B cells outside germinal centers and poor affinity maturation
Authors: James W. Austin, Clarisa M. Buckner, Lela Kardava, Wei Wang, Xiaozhen Zhang, Valerie A. Melson, Ryan G. Swanson, Andrew J. Martins, Julian Q. Zhou, Kenneth B. Hoehn, J. Nicholas Fisk, Yiannis Dimopoulos, Alexander Chassiakos, Sijy O’Dell, Margery G. Smelkinson, Catherine A. Seamon, Richard W. Kwan, Michael C. Sneller, Stefania Pittaluga, Nicole A. Doria-Rose, Adrian McDermott, Yuxing Li, Tae-Wook Chun, Steven H. Kleinstein, John S. Tsang, Constantinos Petrovas, Susan Moir
Journal: Science Translational Medicine (2019)

Nearly all chronic human infections are associated with alterations in the memory B cell (MBC) compartment, including a large expansion of CD19hiT-bethi MBC in the peripheral blood of HIV-infected individuals with chronic viremia. Despite their prevalence, it is unclear how these B cells arise and whether they contribute to the inefficiency of antibody-mediated immunity in chronic infectious diseases. We addressed these questions by characterizing T-bet-expressing B cells in lymph nodes (LN) and identifying a strong T-bet signature among HIV-specific MBC associated with poor immunologic outcome. Confocal microscopy and quantitative imaging revealed that T-bethi B cells in LN of HIV-infected chronically viremic individuals distinctly accumulated outside germinal centers (GC), which are critical for optimal antibody responses. In single-cell analyses, LN T-bethi B cells of HIV-infected individuals were almost exclusively found among CD19hi MBC and expressed reduced GC-homing receptors. Furthermore, HIV-specific B cells of infected individuals were enriched among LN CD19hiT-bethi MBC and displayed a distinct transcriptome, with features similar to CD19hiT-bethi MBC in blood and LN GC B cells (GCBC). LN CD19hiT-bethi MBC were also related to GCBC by B cell receptor (BCR)-based phylogenetic linkage but had lower BCR mutation frequencies and reduced HIV-neutralizing capacity, consistent with diminished participation in GC-mediated affinity selection. Thus, in the setting of chronic immune activation associated with HIV viremia, failure of HIV-specific B cells to enter or remain in GC may help explain the rarity of high-affinity protective antibodies.
A super enhancer controls expression and chromatin architecture within the MHC class II locus
Authors: Parimal Majumder, Joshua T. Lee, Andrew R. Rahmberg, Gaurav Kumar, Tian Mi, Christopher D. Scharer, Jeremy M. Boss
Journal: The Journal of Experimental Medicine (2019)

Super enhancers (SEs) play critical roles in cell type–specific gene regulation. The mechanisms by which such elements work are largely unknown. Two SEs termed DR/DQ-SE and XL9-SE are situated within the human MHC class II locus between the HLA-DRB1 and HLA-DQA1 genes and are highly enriched for disease-causing SNPs. To test the function of these elements, we used CRISPR/Cas9 to generate a series of mutants that deleted the SE. Deletion of DR/DQ-SE resulted in reduced expression of HLA-DRB1 and HLA-DQA1 genes. The SEs were found to interact with each other and the promoters of HLA-DRB1 and HLA-DQA1. DR/DQ-SE also interacted with neighboring CTCF binding sites. Importantly, deletion of DR/DQ-SE reduced the local chromatin interactions, implying that it functions as the organizer for the local three-dimensional architecture. These data provide direct mechanisms by which an MHC-II SE contributes to expression of the locus and suggest how variation in these SEs may contribute to human disease and altered immunity.
Man in His 90s With a History of Tachycardia and Abnormal Findings on Slitlamp Examination of the Cornea
Authors: KieuYen Luu, R. Joel Welch, Glenn Yiu
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib
Authors: Lelia Maria de Almeida Carvalho, Sandra de Oliveira Sapori Avelar, Alyson Haslam, Jennifer Gill, Vinay Prasad
Journal: JAMA Network Open (2019)

When a novel drug is granted accelerated approval, both its on-label and off-label uses must be taken into account.To estimate the potential upper bound of off-label use of erdafitinib to treat advanced cancer with fibroblast growth factor receptor gene (FGFR) alterations, compare it to the upper bound of on-label use in urothelial cancer, and to review studies that may support off-label use.This cross-sectional study used frequency data on FGFR alterations by cancer type and the estimated number of deaths from all cancers for 2019 in the United States. Mortality statistics were used as surrogates for patients with advanced cancer. Analysis was conducted in May 2019.Percentage of patients with an FGFR2 or FGFR3 alteration.Estimated number of patients with advanced cancer expressing an FGFR2 or FGFR3 alteration eligible for off-label use of erdafitinib by cancer type; number of studies investigating FGFR-targeting drugs for patients with cancer; and number of ongoing clinical trials on erdafitinib by cancer type.A total of 15 cancer types had reported FGFR alterations. Of 455 440 estimated patients who died of cancer in 2019, 17 019 (3.7%) were estimated to have FGFR2 or FGFR3 alterations. Of these patients, 12 955 (76.1%) could be eligible for off-label treatment with erdafitinib. A total of 29 completed studies evaluated FGFR-targeting drugs in 11 cancer types, and 10 ongoing studies are studying erdafitinib for different oncological indications.This study indicates that the potential for off-label use of FGFR inhibitors such as erdafitinib spans a number of cancer types and a large patient population. Systematic trials exploring off-label uses may be desirable for drugs that target clear, identifiable molecular alterations because this may be more efficient than off-label use in identifying clinical scenarios where the agent has activity.
Prediction of Patients at Risk of CD19Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia
Authors: Pablo Domizi, Astraea Jager, Jolanda Sarno, Charles G. Mullighan, Stephan Grupp, Elena Sotillo, David M. Barrett, Kara L. Davis
Journal: Blood (2019)
Histone hyperacetylation disrupts core gene regulatory architecture in rhabdomyosarcoma
Authors: Berkley E. Gryder, Silvia Pomella, Carly Sayers, Xiaoli S. Wu, Young Song, Anna M. Chiarella, Sukriti Bagchi, Hsien-Chao Chou, Ranu S. Sinniah, Ashley Walton, Xinyu Wen, Rossella Rota, Nathaniel A. Hathaway, Keji Zhao, Jiji Chen, Christopher R. Vakoc, Jack F. Shern, Benjamin Z. Stanton, Javed Khan
Journal: Nature Genetics (2019)
Annals Graphic Medicine - Fear and Loathing in RA
Authors: Jennifer Ng
Journal: Annals of Internal Medicine (2019)

Web Exclusives3 December 2019Annals Graphic Medicine - Fear and Loathing in RAFREEJennifer NgJennifer NgSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G19-0013 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G18-0013.Author/Illustrator Information: Jennifer Ng is a rheumatologist at Gold Coast University Hospital in Southport, Australia, and an adjunct associate professor at Griffith University (e-mail, jennih.[email protected]com).This article was published at Annals.org on 26 November 2019. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 3 December 2019Volume 171, Issue 11Page: W78KeywordsConflicts of interestDisclosureFearHealth care ePublished: 26 November 2019 Issue Published: 3 December 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Response to comment on “ <i>Aggregatibacter actinomycetemcomitans</i> –induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis”
Authors: Maximilian F. Konig, Jon T. Giles, Ricardo P. Teles, Niki M. Moutsopoulos, Felipe Andrade
Journal: Science Translational Medicine (2018)

Antibodies to leukotoxin A are markers that link Aggregatibacter actinomycetemcomitans-associated periodontitis and rheumatoid arthritis.